Organicell Regenerative Medicine, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a OCEL research report →
Price Chart
About the company
Organicell Regenerative Medicine, Inc. is a clinical-stage biopharmaceutical firm dedicated to pioneering biological therapies for degenerative conditions. Their primary investigational product is Zofin, an acellular biological treatment sourced from perinatal material.
- CEO
- Harry L. Leider FACPE,
- IPO
- 2016
- Employees
- 20
- HQ
- Miami, FL, US
Get TickerSpark's AI analysis on OCEL
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $19.97M
- P/E
- -4.73
- PEG
- 0.16
- P/S
- 2.86
- P/B
- 29.88
- EV/EBITDA
- 236.69
- Div Yield
- 0.00%
- Gross Margin
- 81.52%
- Op Margin
- -59.10%
- Net Margin
- -55.59%
- ROE
- 455.87%
- ROIC
- -511.01%
Latest fiscal year · YoY change
- Revenue
- $5.20M+12.5%
- Gross Profit
- $4.27M+13.0%
- Op Income
- $-5,386,000
- Net Income
- $-5,521,000-17.3%
- EPS
- $-0.86-16.2%
- OCF Growth
- +50.5%
- FCF Growth
- +48.9%
- 52W High
- $4.80
- 52W Low
- $0.90
- 50D MA
- $1.56
- 200D MA
- $2.21
- Beta
- 1.36
- RSI (14)
- 44
- Avg Volume
- 4.72K
No earnings-call transcripts are available for OCEL yet.
- Free Float
- 9796.2%
- Shares Outstanding
- 7.28M
- Float Shares
- 713.50M
of shares held by institutions
1 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 29, 23 | Leider Harry L. | buy | 500,000 |
| Jun 28, 23 | Leider Harry L. | buy | 549,450 |
| Dec 19, 23 | Leider Harry L. | sell | 5,248 |
| Jul 7, 23 | Skycrest Holdings, LLC | buy | 320,710 |
| Jun 29, 23 | Skycrest Holdings, LLC | buy | 200,000 |
| Jun 28, 23 | Skycrest Holdings, LLC | buy | 400,000 |
| Jun 28, 23 | Leider Harry L. | buy | 549,450 |
| Jun 26, 23 | Skycrest Holdings, LLC | buy | 800,000 |
| Sep 6, 23 | Golub Howard Lawrence | other | 50,000,000 |
| Sep 6, 23 | Leider Harry L. | other | 57,000,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our OCEL coverage
Recent articles, reports, and earnings notes.
No research on OCEL yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate OCEL report →RETRANSMISSION: Organicell Regenerative Medicine Rebranding to ZEO ScientifiX
accesswire.com · Mar 7
Organicell Regenerative Medicine Rebranding to ZEO ScientifiX
accesswire.com · Mar 4
Organicell Announces 1-for-200 Reverse Stock Split
accesswire.com · Nov 27
Organicell Reports Interim Results of Phase 1/2A Research Program
accesswire.com · Jul 26
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.